Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 77Neoplasms 69Prostatic Neoplasms 51Colorectal Neoplasms 44Lung Neoplasms 38Carcinoma, Non-Small-Cell Lung 28Hematologic Neoplasms 22Pancreatic Neoplasms 21Neoplasm Metastasis 20Head and Neck Neoplasms 19Urinary Bladder Neoplasms 15Ovarian Neoplasms 15Multiple Myeloma 15Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Motor Activity 11Leukemia, Myeloid, Acute 11Glioblastoma 10Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Gastrointestinal Neoplasms 9Colonic Neoplasms 9Melanoma 8Hematopoietic and Lymphatic System Neoplasm 8Glioma 8Esophageal Neoplasms 8Carcinoma, Renal Cell 8COVID-19 8Anxiety Disorders 8Anatomic Stage I Breast Cancer AJCC v8 8

Interventions

resiniferatoxin 3Ketamine 3Morphine 2Methadone 2Dexmedetomidine 2ziconotide 1substance P-saporin 1Standard of Care 1Sodium Chloride 1Ropivacaine 1Registries 1Pregabalin 1Passive Cutaneous Anaphylaxis 1Midazolam 1Lidocaine 1Infusion Pumps, Implantable 1Hydromorphone 1Fentanyl 1Calcium Dobesilate 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pain, Intractable × Standard of Care × Clear all
NCT04572776 2021-11-09

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Sorrento Therapeutics, Inc.

Phase 3 Withdrawn

Cancer Pain, Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡